Project Grant HT94252510945
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $335K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hamden, CT 06511, USA
Similar Awards
- The U.S. Defense Health Agency awarded a $1,675,000.00 Project Grant to Yale University to support the "DRUG DISCOVERY FOR DYSTONIA AND FRONTOTEMPORAL DEGENERATION" research project. This award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research to transform healthcare for military service members, veterans, and the general public. The project period runs from August 15, 2025 to August 14, 2029 and will...
- The federal Project Grant award titled "TARGETING TDP-43 PROTEIN DYNAMICS IN TRAUMA-ASSOCIATED ALZHEIMER'S DISEASE RELATED DEMENTIA" is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award, totaling $999,965.00, was granted to Yale University on January 15, 2025 for a project period ending on January 14, 2028. The funding supports advanced biomedical research aimed at transforming healthcare for military service...
- The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
- This federal Project Grant award of $249,612 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Yale University to unravel the causal impact of multiple sclerosis (MS)-associated genetic variants on T cell immune tolerance. The award has a performance period from September 1, 2025 to August 31, 2027 and aims to advance the scientific understanding of the underlying mechanisms of MS through innovative biomedical...
- The federal Project Grant award "ROLE OF THE GLYCOME IN TSC BIOMARKER IDENTIFICATION AND MOLECULAR PATHOGENESIS" was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,683,194.00 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will support advanced biomedical research focused on investigating the role of the glycome in identifying biomarkers and understanding the molecular...
- The Defense Health Agency has awarded a $1,674,999.00 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the "PERTURBOMICS IDENTIFICATION OF CRITICAL GENETIC TARGETS IN NK CELLS FOR BREAST CANCER THERAPY" project, which will be conducted from September 1, 2023 to August 31, 2026. The funding will support basic, applied, and advanced biomedical research to transform healthcare for service members and the public...
- This federal Project Grant award of $1,008,999.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Yale University to discover and target endogenous retroviruses in clear cell renal cell carcinoma. The award period runs from September 1, 2025 through August 31, 2029. The project aims to advance biomedical research that can transform healthcare for military service members, veterans, and the broader public. The...
- The Defense Health Agency awarded Brigham & Women's Hospital Inc. a $253,636 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2025 to investigate the role of the secreted factor CTHRC1 in the pathogenesis of tuberous sclerosis complex. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $859,773 to Yale University to conduct research on biomarkers and targets of leptomeningeal disease progression from non-small cell lung cancer brain metastasis. The research project has an award date of May 1, 2025 and an ultimate completion date of April 30, 2028. The research aims to transform healthcare for military service members, veterans,...
- The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...